IDEAS home Printed from https://ideas.repec.org/a/wly/riskan/v41y2021i2p329-348.html
   My bibliography  Save this article

Updated Characterization of Outbreak Response Strategies for 2019–2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain

Author

Listed:
  • Dominika A. Kalkowska
  • Mark A. Pallansch
  • Amanda Wilkinson
  • Ananda S. Bandyopadhyay
  • Jennifer L. Konopka‐Anstadt
  • Cara C. Burns
  • M. Steven Oberste
  • Steven G. F. Wassilak
  • Kamran Badizadegan
  • Kimberly M. Thompson

Abstract

Delays in achieving the global eradication of wild poliovirus transmission continue to postpone subsequent cessation of all oral poliovirus vaccine (OPV) use. Countries must stop OPV use to end all cases of poliomyelitis, including vaccine‐associated paralytic polio (VAPP) and cases caused by vaccine‐derived polioviruses (VDPVs). The Global Polio Eradication Initiative (GPEI) coordinated global cessation of all type 2 OPV (OPV2) use in routine immunization in 2016 but did not successfully end the transmission of type 2 VDPVs (VDPV2s), and consequently continues to use type 2 OPV (OPV2) for outbreak response activities. Using an updated global poliovirus transmission and OPV evolution model, we characterize outbreak response options for 2019–2029 related to responding to VDPV2 outbreaks with a genetically stabilized novel OPV (nOPV2) strain or with the currently licensed monovalent OPV2 (mOPV2). Given uncertainties about the properties of nOPV2, we model different assumptions that appear consistent with the evidence on nOPV2 to date. Using nOPV2 to respond to detected cases may reduce the expected VDPV and VAPP cases and the risk of needing to restart OPV2 use in routine immunization compared to mOPV2 use for outbreak response. The actual properties, availability, and use of nOPV2 will determine its effects on type 2 poliovirus transmission in populations. Even with optimal nOPV2 performance, countries and the GPEI would still likely need to restart OPV2 use in routine immunization in OPV‐using countries if operational improvements in outbreak response to stop the transmission of cVDPV2s are not implemented effectively.

Suggested Citation

  • Dominika A. Kalkowska & Mark A. Pallansch & Amanda Wilkinson & Ananda S. Bandyopadhyay & Jennifer L. Konopka‐Anstadt & Cara C. Burns & M. Steven Oberste & Steven G. F. Wassilak & Kamran Badizadegan & , 2021. "Updated Characterization of Outbreak Response Strategies for 2019–2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain," Risk Analysis, John Wiley & Sons, vol. 41(2), pages 329-348, February.
  • Handle: RePEc:wly:riskan:v:41:y:2021:i:2:p:329-348
    DOI: 10.1111/risa.13622
    as

    Download full text from publisher

    File URL: https://doi.org/10.1111/risa.13622
    Download Restriction: no

    File URL: https://libkey.io/10.1111/risa.13622?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Radboud J. Duintjer Tebbens & Mark A. Pallansch & Dominika A. Kalkowska & Steven G. F. Wassilak & Stephen L. Cochi & Kimberly M. Thompson, 2013. "Characterizing Poliovirus Transmission and Evolution: Insights from Modeling Experiences with Wild and Vaccine‐Related Polioviruses," Risk Analysis, John Wiley & Sons, vol. 33(4), pages 703-749, April.
    2. Radboud J. Duintjer Tebbens & Mark A. Pallansch & Konstantin M. Chumakov & Neal A. Halsey & Tapani Hovi & Philip D. Minor & John F. Modlin & Peter A. Patriarca & Roland W. Sutter & Peter F. Wright & S, 2013. "Review and Assessment of Poliovirus Immunity and Transmission: Synthesis of Knowledge Gaps and Identification of Research Needs," Risk Analysis, John Wiley & Sons, vol. 33(4), pages 606-646, April.
    3. Radboud J. Duintjer Tebbens & Mark A. Pallansch & Konstantin M. Chumakov & Neal A. Halsey & Tapani Hovi & Philip D. Minor & John F. Modlin & Peter A. Patriarca & Roland W. Sutter & Peter F. Wright & S, 2013. "Expert Review on Poliovirus Immunity and Transmission," Risk Analysis, John Wiley & Sons, vol. 33(4), pages 544-605, April.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Dominika A. Kalkowska & Kimberly M. Thompson, 2021. "Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019–2029," Risk Analysis, John Wiley & Sons, vol. 41(2), pages 364-375, February.
    2. Radboud J. Duintjer Tebbens & Kimberly M. Thompson, 2019. "Evaluation of Proactive and Reactive Strategies for Polio Eradication Activities in Pakistan and Afghanistan," Risk Analysis, John Wiley & Sons, vol. 39(2), pages 389-401, February.
    3. Dominika A. Kalkowska & Mark A. Pallansch & Steven G. F. Wassilak & Stephen L. Cochi & Kimberly M. Thompson, 2021. "Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame," Risk Analysis, John Wiley & Sons, vol. 41(2), pages 248-265, February.
    4. Dominika A. Kalkowska & Radboud J. Duintjer Tebbens & Mark A. Pallansch & Kimberly M. Thompson, 2019. "Modeling Undetected Live Poliovirus Circulation After Apparent Interruption of Transmission: Pakistan and Afghanistan," Risk Analysis, John Wiley & Sons, vol. 39(2), pages 402-413, February.
    5. Radboud J. Duintjer Tebbens & Kimberly M. Thompson, 2018. "Using integrated modeling to support the global eradication of vaccine‐preventable diseases," System Dynamics Review, System Dynamics Society, vol. 34(1-2), pages 78-120, January.
    6. Radboud J. Duintjer Tebbens & Mark A. Pallansch & Stephen L. Cochi & Derek T. Ehrhardt & Noha H. Farag & Stephen C. Hadler & Lee M. Hampton & Maureen Martinez & Steve G.F. Wassilak & Kimberly M. Thomp, 2018. "Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations," Risk Analysis, John Wiley & Sons, vol. 38(8), pages 1701-1717, August.
    7. Kimberly M. Thompson & Dominika A. Kalkowska, 2021. "Potential Future Use, Costs, and Value of Poliovirus Vaccines," Risk Analysis, John Wiley & Sons, vol. 41(2), pages 349-363, February.
    8. Kimberly M. Thompson & Mark A. Pallansch & Radboud J. Duintjer Tebbens & Steve G. Wassilak & Stephen L. Cochi, 2013. "Modeling Population Immunity to Support Efforts to End the Transmission of Live Polioviruses," Risk Analysis, John Wiley & Sons, vol. 33(4), pages 647-663, April.
    9. Kimberly M. Thompson, 2013. "Modeling Poliovirus Risks and the Legacy of Polio Eradication," Risk Analysis, John Wiley & Sons, vol. 33(4), pages 505-515, April.
    10. Kimberly M. Thompson & Mark A. Pallansch & Radboud J. Duintjer Tebbens & Steve G. Wassilak & Jong‐Hoon Kim & Stephen L. Cochi, 2013. "Preeradication Vaccine Policy Options for Poliovirus Infection and Disease Control," Risk Analysis, John Wiley & Sons, vol. 33(4), pages 516-543, April.
    11. Dominika A. Kalkowska & Richard Franka & Jeff Higgins & Stephanie D. Kovacs & Joseph C. Forbi & Steven G. F. Wassilak & Mark A. Pallansch & Kimberly M. Thompson, 2021. "Modeling Poliovirus Transmission in Borno and Yobe, Northeast Nigeria," Risk Analysis, John Wiley & Sons, vol. 41(2), pages 289-302, February.
    12. Ternullo S, 2017. "Where We Stand In the Global Eradication of Polio," Global Journal of Pharmacy & Pharmaceutical Sciences, Juniper Publishers Inc., vol. 2(2), pages 30-37, May.
    13. Kimberly M. Thompson & Stephen L. Cochi, 2016. "Modeling and Managing the Risks of Measles and Rubella: A Global Perspective, Part I," Risk Analysis, John Wiley & Sons, vol. 36(7), pages 1288-1296, July.
    14. Negar Darabi & Niyousha Hosseinichimeh, 2020. "System dynamics modeling in health and medicine: a systematic literature review," System Dynamics Review, System Dynamics Society, vol. 36(1), pages 29-73, January.
    15. Kamran Badizadegan & Dominika A. Kalkowska & Kimberly M. Thompson, 2023. "Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame," Medical Decision Making, , vol. 43(7-8), pages 850-862, October.
    16. Radboud J. Duintjer Tebbens & Mark A. Pallansch & Jong‐Hoon Kim & Cara C. Burns & Olen M. Kew & M. Steven Oberste & Ousmane M. Diop & Steven G.F. Wassilak & Stephen L. Cochi & Kimberly M. Thompson, 2013. "Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling the Risks of Circulating Vaccine‐Derived Polioviruses (cVDPVs)," Risk Analysis, John Wiley & Sons, vol. 33(4), pages 680-702, April.
    17. Kimberly M. Thompson & Dominika A. Kalkowska, 2021. "Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame," Risk Analysis, John Wiley & Sons, vol. 41(2), pages 229-247, February.
    18. Radboud J. Duintjer Tebbens & Mark A. Pallansch & Dominika A. Kalkowska & Steven G. F. Wassilak & Stephen L. Cochi & Kimberly M. Thompson, 2013. "Characterizing Poliovirus Transmission and Evolution: Insights from Modeling Experiences with Wild and Vaccine‐Related Polioviruses," Risk Analysis, John Wiley & Sons, vol. 33(4), pages 703-749, April.
    19. Gonzaga, M.N. & de Oliveira, M.M. & Atman, A.P.F., 2023. "Immunity Agent-Based Model (IABM) for epidemiological systems," Chaos, Solitons & Fractals, Elsevier, vol. 176(C).
    20. Kristine Anne C. Vinco & Xerxes G. Malaga, 2021. "Polio Vaccination Literacy Among Mothers of Selected Barangay Health Centers in a Component City," Technium BioChemMed: Journal of Multidisciplinary Research, Biology, Chemistry and Medicine ISSN 2734 - 7990, Technium Science, vol. 2(1), pages 62-78, January.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wly:riskan:v:41:y:2021:i:2:p:329-348. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: https://doi.org/10.1111/(ISSN)1539-6924 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.